clinical trial · NCT07661329
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
YS Life Science Co., Ltd.·phase3·recruiting·n = 600
Primary Open Angle Glaucoma (POAG)Ocular Hypertension (OH)Bimatoprost ophthalmic solution 0.01% YSBPbimatoprost ophthalmic solution 0.01% (Lumigan®)
brief summary
This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd. compared to LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of AbbVie INC in subjects with primary open angle glaucoma (POAG) or ocular hypertension.
started
Jun 2, 2026
primary completion
Nov 1, 2027
completion
Dec 31, 2027
last updated
Sep 23, 2026
official title
A Comparative Randomized, Investigator-Blind, Active-Controlled, Parallel-Group, Multicenter, Clinical Endpoint Study to Evaluate Efficacy and Safety of Bimatoprost Ophthalmic Solution 0.01% (YSBP) of YS Life Science Co., Ltd. (YSLS) and Lumigan® (Bimatoprost Ophthalmic Solution) 0.01% of AbbVie INC, in the Treatment of Subjects With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol